{"name":"UCB Pharma SA","slug":"ucb-pharma-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-11-30","label":"Niravam Phase 3 readout (Stereotypical Prolonged Seizures)","drug":"Niravam","drugSlug":"niravam","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Alprazolam orally disintegrating tablets","genericName":"Alprazolam orally disintegrating tablets","slug":"alprazolam-orally-disintegrating-tablets","indication":"Anxiety disorders","status":"phase_3"},{"name":"SPM 927","genericName":"SPM 927","slug":"spm-927","indication":"Epilepsy (focal seizures)","status":"phase_3"},{"name":"SSRI/SNRI","genericName":"SSRI/SNRI","slug":"ssri-snri","indication":"Major depressive disorder","status":"marketed"},{"name":"Brivaracetam (ucb 34714)","genericName":"Brivaracetam (ucb 34714)","slug":"brivaracetam-ucb-34714","indication":"Adjunctive treatment of partial-onset seizures in epilepsy","status":"phase_3"},{"name":"Brivaracetam bolus","genericName":"Brivaracetam bolus","slug":"brivaracetam-bolus","indication":"Adjunctive treatment of partial-onset seizures in patients with epilepsy","status":"phase_3"},{"name":"Brivaracetam infusion","genericName":"Brivaracetam infusion","slug":"brivaracetam-infusion","indication":"Adjunctive treatment of partial-onset seizures in patients with epilepsy","status":"phase_3"},{"name":"Keppra XR (Levetiracetam XR)","genericName":"Keppra XR (Levetiracetam XR)","slug":"keppra-xr-levetiracetam-xr","indication":"Adjunctive therapy for partial-onset seizures in epilepsy","status":"phase_3"},{"name":"Keppra® extended release formulation - XR","genericName":"Keppra® extended release formulation - XR","slug":"keppra-extended-release-formulation-xr","indication":"Adjunctive therapy for partial-onset seizures","status":"phase_3"},{"name":"Levetiracetam (Keppra)","genericName":"Levetiracetam (Keppra)","slug":"levetiracetam-keppra","indication":"Partial-onset seizures (adjunctive therapy)","status":"marketed"},{"name":"Methylphenidate Extended Release Capsules","genericName":"Methylphenidate Extended Release Capsules","slug":"methylphenidate-extended-release-capsules","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"Neupro®","genericName":"Neupro®","slug":"neupro","indication":"Parkinson's disease (early-stage and advanced)","status":"marketed"},{"name":"SPM 929","genericName":"SPM 929","slug":"spm-929","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Niravam","genericName":"Niravam","slug":"niravam","indication":"Other","status":"marketed"},{"name":"CDP6038","genericName":"CDP6038","slug":"cdp6038","indication":"Other","status":"phase_2"},{"name":"CDP7657","genericName":"CDP7657","slug":"cdp7657","indication":"Other","status":"phase_1"},{"name":"Cetirizine tablets","genericName":"Cetirizine tablets","slug":"cetirizine-tablets","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Kemstro","genericName":"Kemstro","slug":"kemstro","indication":"Other","status":"marketed"},{"name":"Levocetirizine (drug)","genericName":"Levocetirizine (drug)","slug":"levocetirizine-drug","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Levocetirizine oral solution","genericName":"Levocetirizine oral solution","slug":"levocetirizine-oral-solution","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Levocetirizine tablets","genericName":"Levocetirizine tablets","slug":"levocetirizine-tablets","indication":"Allergic rhinitis","status":"phase_2"},{"name":"Placebo-Cetirizine","genericName":"Placebo-Cetirizine","slug":"placebo-cetirizine","indication":"Allergic rhinitis","status":"phase_3"},{"name":"Placebo-Levocetirizine","genericName":"Placebo-Levocetirizine","slug":"placebo-levocetirizine","indication":"Allergic rhinitis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Certolizumab Pegol (CZP)","genericName":"Certolizumab Pegol (CZP)","slug":"certolizumab-pegol-czp","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Certolizumab pegol (CDP870)","genericName":"Certolizumab pegol (CDP870)","slug":"certolizumab-pegol-cdp870","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo + Methotrexate (MTX)","genericName":"Placebo + Methotrexate (MTX)","slug":"placebo-methotrexate-mtx","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Cetirizine drops","genericName":"Cetirizine drops","slug":"cetirizine-drops","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Placebo to Pentoxifylline oral","genericName":"Placebo to Pentoxifylline oral","slug":"placebo-to-pentoxifylline-oral","indication":"Intermittent claudication (peripheral arterial disease)","status":"phase_3"}]}],"pipeline":[{"name":"Alprazolam orally disintegrating tablets","genericName":"Alprazolam orally disintegrating tablets","slug":"alprazolam-orally-disintegrating-tablets","phase":"phase_3","mechanism":"Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects.","indications":["Anxiety disorders","Panic disorder","Anxiety associated with depression"],"catalyst":""},{"name":"Niravam","genericName":"Niravam","slug":"niravam","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPM 927","genericName":"SPM 927","slug":"spm-927","phase":"phase_3","mechanism":"SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity.","indications":["Epilepsy (focal seizures)","Generalized seizures"],"catalyst":""},{"name":"SSRI/SNRI","genericName":"SSRI/SNRI","slug":"ssri-snri","phase":"marketed","mechanism":"SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing.","indications":["Major depressive disorder","Generalized anxiety disorder","Panic disorder","Social anxiety disorder","Obsessive-compulsive disorder"],"catalyst":""},{"name":"Brivaracetam (ucb 34714)","genericName":"Brivaracetam (ucb 34714)","slug":"brivaracetam-ucb-34714","phase":"phase_3","mechanism":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","indications":["Adjunctive treatment of partial-onset seizures in epilepsy","Generalized tonic-clonic seizures (pipeline indication)"],"catalyst":""},{"name":"Brivaracetam bolus","genericName":"Brivaracetam bolus","slug":"brivaracetam-bolus","phase":"phase_3","mechanism":"Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand that modulates neurotransmitter release to reduce seizure activity.","indications":["Adjunctive treatment of partial-onset seizures in patients with epilepsy","Acute seizure management (intravenous bolus formulation)"],"catalyst":""},{"name":"Brivaracetam infusion","genericName":"Brivaracetam infusion","slug":"brivaracetam-infusion","phase":"phase_3","mechanism":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","indications":["Adjunctive treatment of partial-onset seizures in patients with epilepsy","Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy"],"catalyst":""},{"name":"CDP6038","genericName":"CDP6038","slug":"cdp6038","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CDP7657","genericName":"CDP7657","slug":"cdp7657","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Certolizumab Pegol (CZP)","genericName":"Certolizumab Pegol (CZP)","slug":"certolizumab-pegol-czp","phase":"marketed","mechanism":"Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"Certolizumab pegol (CDP870)","genericName":"Certolizumab pegol (CDP870)","slug":"certolizumab-pegol-cdp870","phase":"phase_3","mechanism":"Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"Cetirizine drops","genericName":"Cetirizine drops","slug":"cetirizine-drops","phase":"marketed","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis","Allergic asthma (adjunctive)"],"catalyst":""},{"name":"Cetirizine tablets","genericName":"Cetirizine tablets","slug":"cetirizine-tablets","phase":"marketed","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, reducing allergic symptoms.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Kemstro","genericName":"Kemstro","slug":"kemstro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Keppra XR (Levetiracetam XR)","genericName":"Keppra XR (Levetiracetam XR)","slug":"keppra-xr-levetiracetam-xr","phase":"phase_3","mechanism":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","indications":["Adjunctive therapy for partial-onset seizures in epilepsy","Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy","Adjunctive therapy for primary generalized tonic-clonic seizures"],"catalyst":""},{"name":"Keppra® extended release formulation - XR","genericName":"Keppra® extended release formulation - XR","slug":"keppra-extended-release-formulation-xr","phase":"phase_3","mechanism":"Levetiracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizure propagation.","indications":["Adjunctive therapy for partial-onset seizures","Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy","Adjunctive therapy for primary generalized tonic-clonic seizures"],"catalyst":""},{"name":"Levetiracetam (Keppra)","genericName":"Levetiracetam (Keppra)","slug":"levetiracetam-keppra","phase":"marketed","mechanism":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","indications":["Partial-onset seizures (adjunctive therapy)","Myoclonic seizures in patients with juvenile myoclonic epilepsy (adjunctive therapy)","Primary generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"Levocetirizine (drug)","genericName":"Levocetirizine (drug)","slug":"levocetirizine-drug","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Levocetirizine oral solution","genericName":"Levocetirizine oral solution","slug":"levocetirizine-oral-solution","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Levocetirizine tablets","genericName":"Levocetirizine tablets","slug":"levocetirizine-tablets","phase":"phase_2","mechanism":"Selective histamine H1 receptor antagonist","indications":["Allergic rhinitis","Chronic urticaria"],"catalyst":""},{"name":"Methylphenidate Extended Release Capsules","genericName":"Methylphenidate Extended Release Capsules","slug":"methylphenidate-extended-release-capsules","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults","Narcolepsy"],"catalyst":""},{"name":"Neupro®","genericName":"Neupro®","slug":"neupro","phase":"marketed","mechanism":"Neupro is a dopamine agonist that stimulates dopamine receptors in the brain to restore dopamine signaling in patients with Parkinson's disease and restless legs syndrome.","indications":["Parkinson's disease (early-stage and advanced)","Restless legs syndrome (moderate to severe)"],"catalyst":""},{"name":"Placebo + Methotrexate (MTX)","genericName":"Placebo + Methotrexate (MTX)","slug":"placebo-methotrexate-mtx","phase":"phase_3","mechanism":"Methotrexate inhibits dihydrofolate reductase to suppress DNA synthesis and reduce inflammatory immune cell proliferation.","indications":["Rheumatoid arthritis","Other autoimmune/inflammatory conditions (specific indication dependent on trial protocol)"],"catalyst":""},{"name":"Placebo to Pentoxifylline oral","genericName":"Placebo to Pentoxifylline oral","slug":"placebo-to-pentoxifylline-oral","phase":"phase_3","mechanism":"Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.","indications":["Intermittent claudication (peripheral arterial disease)","Diabetic angiopathies","Trophic disorders and ischemic ulcers"],"catalyst":""},{"name":"Placebo-Cetirizine","genericName":"Placebo-Cetirizine","slug":"placebo-cetirizine","phase":"phase_3","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems.","indications":["Allergic rhinitis","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Placebo-Levocetirizine","genericName":"Placebo-Levocetirizine","slug":"placebo-levocetirizine","phase":"phase_3","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","indications":["Allergic rhinitis","Chronic urticaria"],"catalyst":""},{"name":"SPM 929","genericName":"SPM 929","slug":"spm-929","phase":"phase_3","mechanism":"SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQYlhadWFaT01Yb2djVmhxTFlpYWh6ZlRVUzRQNEg1bnJadV9qMkxfYXRLbzZ1S2dLUDRpNEpxMmJSZjVTNXM0TFFXa0hES19mc2E4TkNaX1dkWTFFNHVidzdRbDZDdGh4VUNTbXMxRkxEMTNtSU1UY2IwZDJGRFE4ZVFtQ1F4UDFp?oc=5","date":"2026-02-16","type":"deal","source":"Meyka","summary":"Goldman Sachs Maintains Buy on UCBJF UCB SA Feb 2026 - Meyka","headline":"Goldman Sachs Maintains Buy on UCBJF UCB SA Feb 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVjNqUnRFNk51aWdrMUpSWHdaQUlaclNMb09JX1FSelUxb0R0b1JFX09OU29MMzh4cEFnTnljc2tINXBMWF9aWmpvUWI3T2lOeHRPLXZwRFBHdGxBdHE2Q3JjMzVmOS1raDJDbHNZeDJOU3pQS2RzMG9uOFBza2pnUTFaOFQ4c1FodE94ME5IUDZXZmlsR2hNaTZ0eTlwQ3RnTEZON0ZTV040OVRTM0Vtb3g3US1nTkZwQ0gtbGl1c0tmdE81U1pCS2tkZi03enNQSlpJUUtnRnRuVDBmUFpiUmI2V1Ffd1pFVFJNRWtfMWF2RDhNNUd5S0pQakcyM2hfclJmNG5ueW9FUjc2TGxCS2hfQThnMmdLM3BvWWlDVFlIX2dqVnJ6OC1IUllwOFBLejdTeGdEbjNXcktENV8xdGxlSUY?oc=5","date":"2026-01-29","type":"earnings","source":"Barchart.com","summary":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchar","headline":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Apti","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"simplywall.st","summary":"UCB SA's (EBR:UCB) Stock Is Going Strong: Have Financials A Role To Play? - simplywall.st","headline":"UCB SA's (EBR:UCB) Stock Is Going Strong: Have Financials A Role To Play?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQ3ZmZTZqMFZXVU5OQl9Ec3BCTzlQQ2h0a0ZWV01yVXNIRGEyYkRreDFGZXNsbm9hZEdJSk41dDhpWmplMTZ5VGUtbmdMT3FPRXJ4Q1NoSzM5RzNPR2ppN3hfNy1hOUJQVXZqS3plclg2WGdQTFY0S0hUQVJmcFdiZXg1VGJjR0thYVYxZWNpMDRKUTlRdU9hNjJib05hNXgzX1gyNzNFSTJSR1JDd2ZMdEthcVdtUlVybk1STDdVU1A0R2c?oc=5","date":"2026-01-12","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About UCB S.A.: Is This Quiet Biotech Stock a Hidden Monster or Total Mirage? - AD HOC NEWS","headline":"The Truth About UCB S.A.: Is This Quiet Biotech Stock a Hidden Monster or Total Mirage?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQYnptRTBlQ2xqWXVrTTQ4OTZsN2NFeGxUSlNQZnd2UjJZa2hTeXJDcE52WXRpSGVTQVZ2QTBpcVhLMW9FeDc5OVJNbVBiVWEzUldwTTl2N29zZG9waDBzNGhmelZjaVRObHNsQmV0UWdrZEEyR2czRUR2ZjZIcm5GdTRvQmdrMjgwWE40aU5TV2pRbENjS0FjX1dqaW1Bc28xbF9JQWowVC1ublYtcTlrU3dUN0FLR2taLTNsTFR4X2M?oc=5","date":"2026-01-08","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About UCB S.A.: Quiet Pharma Giant That Could Shock Your Portfolio - AD HOC NEWS","headline":"The Truth About UCB S.A.: Quiet Pharma Giant That Could Shock Your Portfolio","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-14","type":"earnings","source":"simplywall.st","summary":"Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher - simplywall.st","headline":"Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxObFJCTjFJNzBMSnl1aUYweW1zcTd6WnpiNlJzdDVOQlFtZUFFNzhBMDVyZk95Mk9aZGU5eWxJMWEtdnNfQ2ltZnpoMWtLbjIxMENseEFDc1BWZ2NvOFNNNHVvaURhM242Mk1ENTdQS2FSVjJDQVExeVItcldYb0xLZDVFNlRqQmdqdkk1dWFFTEdDQXh3RFlqdndoSUQ4VXk5cDRTWlprcTFzSkc1MEE?oc=5","date":"2025-07-31","type":"regulatory","source":"Bloomberg.com","summary":"UCB Forecasts Record Sales on Demand for Skin Disease Drug - Bloomberg.com","headline":"UCB Forecasts Record Sales on Demand for Skin Disease Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPWmdydm41akl6Y3VGd1NUSlFObGxQOU93MEswRWpUdEFjNFpUWkRFZnhVTXNwcG9nWTBtZFB5ak5RMjlaVi1NUFR6TzZHRkJlZmwwa1FxMHVQRzVlQ0tzdzNaTThfRkhmZFZISWxGRjZiNWxYbGQ3aDRNbkZnNThhTzc0dGtPaFRIR29tR1hpMUFwZkJMQWJHOS1WdWJzS3FWdFBlSWVR?oc=5","date":"2025-06-14","type":"pipeline","source":"Global Atlanta","summary":"Belgian Pharma Giant With Atlanta Base to Invest Billions in U.S. Factory - Global Atlanta","headline":"Belgian Pharma Giant With Atlanta Base to Invest Billions in U.S. Factory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZ3Q5LUhQYk1xa19iTW53NWpKOU1UQXZRQTdtMUZnVG9oeGpEQ25STXdhOU1vSFIxQllPbTdSVkpGc0hoNTl5d2w2LVE5WWJVb1JCSUtvZlg1aTBLd2o3allLMHNKQVFyMlVxejVodU9CY0ZYdnBnX1BwX1hlOWlFbjlFR0pxeENibGptZ29OR1VpOVFaQzQ1VWI5V25hc1czS0hQTk9Ld3hNOGJaUFhHNFdNWTh1b2dHV0MtaXpQZHUwTHA4aFpZQXRsTG9KR3p0RTlUSFJlZmRDTGkxRW1xZw?oc=5","date":"2025-06-13","type":"pipeline","source":"Citeline News & Insights","summary":"UCB Follows Fellow European Pharmas With Major US Investment - Citeline News & Insights","headline":"UCB Follows Fellow European Pharmas With Major US Investment - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPbHE0Mm9YMGxVUkZ3dDZDNDA1Wnl1VndPOTBZSWNhQ19zbE1NMjA5TDJnc3pEdHR1Mnd5WU5UV1JlSEFQVWI2a1EwNVVjNmx6MV9yajVaZjRqbHRFdEtLdndHVEM4dVVvTEpaaVFlYjF6cHhzLXBvcVdCMDlyMGZqRjFMZ3k3Vk9DbWNDV2tiRU9kN3hjLS14Qk9vaU1pay1vX0ROZmlkenZ6akgwM3hMTzFHcGEtYldmSHVIQmpvME50NjctWFpv?oc=5","date":"2025-06-12","type":"pipeline","source":"UCB","summary":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity - UCB","headline":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTWZ0dk01XzUtMHdnQmE4UXY2RHFaMHV5VmNtWWl1VThnU2ZzTTh0M1VuOG5na0RUTUt3R3BieWZXZHRCLXJaVlBCTWtfcWp1UU9aM1VqVHJjWFBmbWc4ZWlIN1ROeDZGVjUyLVhGeHdDbjJGbHBVM0UtdTJCUmNaMzVUVEE5Mm5wMWFUMXJ2elZKVVF0bDIzM1F3RnE?oc=5","date":"2023-05-30","type":"regulatory","source":"Fierce Pharma","summary":"UPDATED: Belgium's UCB Pharma hit with FDA Form 483 after April inspection - Fierce Pharma","headline":"UPDATED: Belgium's UCB Pharma hit with FDA Form 483 after April inspection","sentiment":"neutral"}],"patents":[],"drugCount":27,"phaseCounts":{"phase_3":13,"marketed":11,"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}